Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290687 · ClinicalTrials.gov registry record · Phase 2
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
A Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06290687: Recruiting Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder, sponsored by Case Comprehensive Cancer Center.
NCT06290687 is a Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290687, a Phase 2 study of Muscle-Invasive Bladder Carcinoma and Malignant Neoplasm of Bladder, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy.
Primary Outcome
Recurrence-Free Survival (RFS) is defined as the time from post-surgery baseline scan (revealing no recurrent/metastatic disease) until the first occurrence of either local or distant recurrence as assessed by CT or MRI and/or biopsy. The primary outcome of distant RFS will be assessed via Kaplan-Meier analysis
Conditions Studied
Interventions
- DRUG Neoadjuvant Chemotherapy
- PROCEDURE Partial cystectomy with Extended pelvic lymph node dissection
- DRUG Adjuvant systemic therapy
Study Locations (1)
Ohio
- Glickman Urological and Kidney Institute, Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2027-12-29 |
| Phase | Phase 2 |
What NCT06290687 shows while recruiting
NCT06290687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Neoadjuvant Chemotherapy is the first listed.
NCT06290687 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06290687 about?
NCT06290687 is a clinical study titled "Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy". The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and ...
What is the current status of trial NCT06290687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-02-18. Estimated completion is 2027-12-29.
What conditions does trial NCT06290687 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma, Malignant Neoplasm of Bladder.
What interventions are being tested in trial NCT06290687?
The interventions under investigation include: Neoadjuvant Chemotherapy (DRUG), Partial cystectomy with Extended pelvic lymph node dissection (PROCEDURE), Adjuvant systemic therapy (DRUG).
Who is sponsoring clinical trial NCT06290687?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290687 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06290687's enrollment target sits among peer trials
40 8th of 14 higher than 7 of 14 other Muscle-Invasive Bladder Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Muscle-Invasive Bladder Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITING · Phase 2
-
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
RECRUITING · Phase 2
-
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI